Table of Contents
ISRN AIDS
Volume 2013, Article ID 358294, 10 pages
http://dx.doi.org/10.1155/2013/358294
Research Article

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

1Department of Microbiology and Immunology, McGill University Health Centre, Room A5-140, 1650 Cedar Avenue, Montreal, QC, Canada H3G 1A4
2Montreal General Hospital, Flowcytometry Laboratory, 1650 Cedar Avenue, Room C10-166, Montreal, QC, Canada H3G 1A4
3LAC+USC Medical Center, 1200 N State Street, Room IPT-C4E100, Los Angeles, CA 90033, USA
4Janssen Services, LLC, Clinical Affairs, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA

Received 12 August 2013; Accepted 17 November 2013

Academic Editors: G. D'ettorre and C. Petrovas

Copyright © 2013 Christos Tsoukas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Kestens, G. Vanham, C. Vereecken et al., “Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection,” Clinical and Experimental Immunology, vol. 95, no. 3, pp. 436–441, 1994. View at Google Scholar · View at Scopus
  2. M. Levacher, F. Hulstaert, S. Tallet, S. Ullery, J. J. Pocidalo, and B. A. Bach, “The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value,” Clinical and Experimental Immunology, vol. 90, no. 3, pp. 376–382, 1992. View at Google Scholar · View at Scopus
  3. J. V. Giorgi, H.-N. Ho, K. Hirji et al., “CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels,” Journal of Infectious Diseases, vol. 170, no. 4, pp. 775–781, 1994. View at Google Scholar · View at Scopus
  4. S. A. Klein, J. M. Dobmeyer, T. S. Dobmeyer et al., “Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry,” AIDS, vol. 11, no. 9, pp. 1111–1118, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Liu, W. G. Cumberland, L. E. Hultin, H. E. Prince, R. Detels, and J. V. Giorgi, “Elevated CD38 antigen expression on CD8+ T cells Is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS Cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 16, no. 2, pp. 83–92, 1997. View at Google Scholar · View at Scopus
  6. M.-L. Dion, J.-F. Poulin, R. Bordi et al., “HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation,” Immunity, vol. 21, no. 6, pp. 757–768, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Landay, B. Ohlsson-Wilhelm, and J. V. Giorgi, “Application of flow cytometry to the study of HIV infection,” AIDS, vol. 4, no. 6, pp. 479–497, 1990. View at Google Scholar · View at Scopus
  8. J. B. Margolick, A. Munoz, A. D. Donnenberg et al., “Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort study,” Nature Medicine, vol. 1, no. 7, pp. 674–680, 1995. View at Publisher · View at Google Scholar
  9. L. Kestens, G. Vanham, P. Gigase et al., “Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection,” AIDS, vol. 6, no. 8, pp. 793–797, 1992. View at Google Scholar · View at Scopus
  10. V. Appay, J. R. Almeida, D. Sauce, B. Autran, and L. Papagno, “Accelerated immune senescence and HIV-1 infection,” Experimental Gerontology, vol. 42, no. 5, pp. 432–437, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. P. Aries, B. Schaaf, C. Muller, R. H. Dennin, and K. Dalhoff, “Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression,” Journal of Molecular Medicine, vol. 73, no. 12, pp. 591–593, 1995. View at Google Scholar · View at Scopus
  12. T. H. Mogensen, J. Melchjorsen, C. S. Larsen, and S. R. Paludan, “Innate immune recognition and activation during HIV infection,” Retrovirology, vol. 7, article 54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Peter, A. Ehret, C. Berndt, and P. H. Krammer, “AIDS and the death receptors,” British Medical Bulletin, vol. 53, no. 3, pp. 604–616, 1997. View at Google Scholar · View at Scopus
  14. Z. Bentwich, A. Kalinkovich, Z. Weisman, and Z. Grossman, “Immune activation in the context of HIV infection,” Clinical and Experimental Immunology, vol. 111, no. 1, pp. 1–2, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Grossman, M. Meier-Schellersheim, W. E. Paul, and L. J. Picker, “Pathogenesis of HIV infection: what the virus spares is as important as what it destroys,” Nature Medicine, vol. 12, no. 3, pp. 289–295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. D. Hazenberg, D. Hamann, H. Schuitemaker, and F. Miedema, “T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock,” Nature Immunology, vol. 1, no. 4, pp. 285–289, 2000. View at Google Scholar · View at Scopus
  17. L. A. Trimble, P. Shankar, M. Patterson, J. P. Daily, and J. Lieberman, “Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3ζ and CD28, key signaling molecules for T-cell activation,” Journal of Virology, vol. 74, no. 16, pp. 7320–7330, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. J. H. Vingerhoets, G. L. Vanham, L. L. Kestens et al., “Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8+ T cells from HIV-infected subjects,” Clinical and Experimental Immunology, vol. 100, no. 3, pp. 425–433, 1995. View at Google Scholar · View at Scopus
  19. S. T. Parish, J. E. Wu, and R. B. Effros, “Sustained CD28 expression delays multiple features of replicative senescence in human CD8 T lymphocytes,” Journal of Clinical Immunology, vol. 30, no. 6, pp. 798–805, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. V. I. Avelino-Silva, Y.-L. Ho, T. J. Avelino-Silva, and S. D. S. Santos, “Aging and HIV infection,” Ageing Research Reviews, vol. 10, no. 1, pp. 163–172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. K. L. Wood, H. L. Twigg III, and A. I. Doseff, “Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation,” Frontiers in Bioscience, vol. 14, no. 10, pp. 3771–3781, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. V. Giorgi, Z. Liu, L. E. Hultin, W. G. Cumberland, K. Hennessey, and R. Detels, “Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up,” Journal of Acquired Immune Deficiency Syndromes, vol. 6, no. 8, pp. 904–912, 1993. View at Google Scholar · View at Scopus
  23. M. Clerici and G. M. Shearer, “A TH1TH2 switch is a critical step in the etiology of HIV infection,” Immunology Today, vol. 14, no. 3, pp. 107–111, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Autran, G. Carcelain, T. S. Li et al., “Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease,” Science, vol. 277, no. 5322, pp. 112–116, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Estaquier, J.-D. Leliévre, F. Petit et al., “Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4+ T-cell death,” Journal of Virology, vol. 76, no. 12, pp. 5966–5973, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. A. D. Badley, K. Parato, D. W. Cameron et al., “Dynamic correlation of apoptosis and immune activation during treatment of HIV infection,” Cell Death and Differentiation, vol. 6, no. 5, pp. 420–432, 1999. View at Google Scholar · View at Scopus
  27. M. Goicoechea, D. M. Smith, L. Liu et al., “Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA,” Journal of Infectious Diseases, vol. 194, no. 1, pp. 29–37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. S. A. Riddler, R. Haubrich, A. G. DiRienzo et al., “Class-sparing regimens for initial treatment of HIV-1 infection,” The New England Journal of Medicine, vol. 358, no. 20, pp. 2095–2106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Pichenot, S. Deuffic-Burban, L. Cuzin, and Y. Yazdanpanah, “Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials,” HIV Medicine, vol. 13, no. 3, pp. 148–155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Llibre, M. J. Buzón, M. Massanella et al., “Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study,” Antiviral Therapy, vol. 17, no. 2, pp. 355–364, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Hatano, T. L. Hayes, V. Dahl et al., “A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response,” Journal of Infectious Diseases, vol. 203, no. 7, pp. 960–968, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Byakwaga, M. Kelly, D. F. J. Purcell et al., “Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial,” Journal of Infectious Diseases, vol. 204, no. 10, pp. 1532–1540, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Currier, D. A. Bridge, D. Hagins et al., “Sex-based outcomes of Darunavir-Ritonavir therapy: a single-group trial,” Annals of Internal Medicine, vol. 153, no. 6, pp. 349–357, 2010. View at Google Scholar · View at Scopus
  34. J. B. Angel, K. G. Parato, A. Kumar et al., “Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression,” Journal of Infectious Diseases, vol. 183, no. 4, pp. 546–554, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Ullum, T. Katzenstein, H. Aladdin et al., “Immunological changes in Human Immunodeficiency Virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment,” Scandinavian Journal of Immunology, vol. 49, no. 5, pp. 539–547, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. R. C. Kaplan, C. M. Parrinello, H. N. Hodis et al., “Impact of HAART initiation on immune regulation (activation/senescence) in aging HIV-infected women: Women's Interagency HIV study,” in Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Wash, USA, 2012.
  37. C. Garrido, N. Rallón, V. Soriano et al., “Mechanisms involved in CD4 gains in HIV-infected patients switched to raltegravir,” AIDS, vol. 26, no. 5, pp. 551–557, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. R. T. Steigbigel, D. A. Cooper, P. N. Kumar et al., “Raltegravir with optimized background therapy for resistant HIV-1 infection,” The New England Journal of Medicine, vol. 359, no. 4, pp. 339–354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. M.-L. Gougeon, H. Lecoeur, and Y. Sasaki, “Apoptosis and the CD95 system in HIV disease: impact of Highly Active Anti-Retroviral Therapy (HAART),” Immunology Letters, vol. 66, no. 1–3, pp. 97–103, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. C. G. Lange, M. M. Lederman, K. Medvik et al., “Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection,” AIDS, vol. 17, no. 14, pp. 2015–2023, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Niehues, G. Horneff, S. Knipp, O. Adams, and V. Wahn, “Treatment-resistant expansion of CD8+CD28-cells in pediatric HIV infection,” Pediatric Research, vol. 47, no. 3, pp. 418–421, 2000. View at Google Scholar · View at Scopus
  42. C. G. Lange and M. M. Lederman, “Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 1, pp. 1–4, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Hill, J. Montaner, M. Lederman, A. Cutrell, S. Tortell, and D. Thorborn, “Discordant CD4/RNA responses to HAART are strongly associated with high baseline CD4 count and low HIV RNA: analysis of 406 naive patients,” in Proceedings of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, Calif, USA, 1999.
  44. R. C. Kaplan, E. Sinclair, A. L. Landay et al., “T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women,” Journal of Infectious Diseases, vol. 203, no. 4, pp. 452–463, 2011. View at Publisher · View at Google Scholar · View at Scopus